IL173300A0 - Compositions for encapsulation and controlled release - Google Patents

Compositions for encapsulation and controlled release

Info

Publication number
IL173300A0
IL173300A0 IL173300A IL17330006A IL173300A0 IL 173300 A0 IL173300 A0 IL 173300A0 IL 173300 A IL173300 A IL 173300A IL 17330006 A IL17330006 A IL 17330006A IL 173300 A0 IL173300 A0 IL 173300A0
Authority
IL
Israel
Prior art keywords
encapsulation
compositions
controlled release
release
controlled
Prior art date
Application number
IL173300A
Other languages
English (en)
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Publication of IL173300A0 publication Critical patent/IL173300A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
IL173300A 2003-07-31 2006-01-23 Compositions for encapsulation and controlled release IL173300A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49163103P 2003-07-31 2003-07-31
US49163803P 2003-07-31 2003-07-31
PCT/US2004/024429 WO2005012488A2 (en) 2003-07-31 2004-07-29 Compositions for encapsulation and controlled release

Publications (1)

Publication Number Publication Date
IL173300A0 true IL173300A0 (en) 2006-06-11

Family

ID=34118876

Family Applications (2)

Application Number Title Priority Date Filing Date
IL173300A IL173300A0 (en) 2003-07-31 2006-01-23 Compositions for encapsulation and controlled release
IL173301A IL173301A0 (en) 2003-07-31 2006-01-23 Bioactive compositions comprising triazines

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL173301A IL173301A0 (en) 2003-07-31 2006-01-23 Bioactive compositions comprising triazines

Country Status (11)

Country Link
US (2) US20080039533A1 (cg-RX-API-DMAC10.html)
EP (2) EP1651185A1 (cg-RX-API-DMAC10.html)
JP (2) JP2007500712A (cg-RX-API-DMAC10.html)
KR (2) KR20060056354A (cg-RX-API-DMAC10.html)
AU (2) AU2004261243A1 (cg-RX-API-DMAC10.html)
BR (2) BRPI0413143A (cg-RX-API-DMAC10.html)
CA (2) CA2533128A1 (cg-RX-API-DMAC10.html)
IL (2) IL173300A0 (cg-RX-API-DMAC10.html)
MX (2) MXPA06001054A (cg-RX-API-DMAC10.html)
RU (2) RU2006102187A (cg-RX-API-DMAC10.html)
WO (2) WO2005012488A2 (cg-RX-API-DMAC10.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
RU2006105101A (ru) * 2003-08-27 2007-10-10 3М Инновейтив Пропертиз Компани (US) Арилокси и арилалкиленокси замещенные имидазохинолины
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
AR046172A1 (es) 2003-10-03 2005-11-30 3M Innovative Properties Co Pirazolopiridinas y sus analogos; composiciones farmaceuticas que los contienen y su uso en la inhibicion de la biosintesis de citocinas
AR046781A1 (es) 2003-11-25 2005-12-21 3M Innovative Properties Co Derivados de imidazoquinolinas. composiciones farmaceuticas.
US8541438B2 (en) * 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US7247723B2 (en) 2004-11-24 2007-07-24 3M Innovative Properties Company Metallic chromonic compounds
US7582330B2 (en) 2004-11-24 2009-09-01 3M Innovative Properties Counsel Method for making metallic nanostructures
US7687115B2 (en) 2004-11-24 2010-03-30 3M Innovative Properties Company Method for making nanostructured surfaces
EP1831226B1 (en) 2004-12-30 2012-08-08 3M Innovative Properties Company Chiral tetracyclic compounds inducing interferon biosynthesis
AU2005326708C1 (en) 2004-12-30 2012-08-30 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
AU2006212765B2 (en) * 2005-02-09 2012-02-02 3M Innovative Properties Company Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
JP2008530252A (ja) 2005-02-09 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド オキシムおよびヒドロキシルアミンで置換されたチアゾロ［４，５−ｃ］環化合物ならびに方法
JP2008532933A (ja) * 2005-02-11 2008-08-21 コーリー ファーマシューティカル グループ，インコーポレイテッド 置換イミダゾキノリン類および置換イミダゾナフチリジン類
EP1850849A2 (en) * 2005-02-23 2007-11-07 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
US8158794B2 (en) * 2005-02-23 2012-04-17 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
CA2598639A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazonaphthyridines
EP1851224A2 (en) * 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinolines
CA2601067A1 (en) 2005-05-04 2006-11-09 Medigene Ag Method of administering a cationic liposomal preparation comprising paclitaxel
AU2006287270A1 (en) * 2005-09-09 2007-03-15 Coley Pharmaceutical Group, Inc. Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
US7629027B2 (en) 2005-10-14 2009-12-08 3M Innovative Properties Company Method for making chromonic nanoparticles
US7718716B2 (en) 2005-10-14 2010-05-18 3M Innovative Properties Company Chromonic nanoparticles containing bioactive compounds
ES2429170T3 (es) 2005-11-04 2013-11-13 3M Innovative Properties Company 1H-Imidazoquinolinas sustituidas con hidroxilo y alcoxilo y métodos
US7807661B2 (en) 2005-12-08 2010-10-05 3M Innovative Properties Company Silver ion releasing articles and methods of manufacture
US8092710B2 (en) * 2005-12-19 2012-01-10 3M Innovative Properties Company Hierarchical chromonic structures
US7601769B2 (en) 2005-12-19 2009-10-13 3M Innovative Peroperties Company Multilayered chromonic structures
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
US7824732B2 (en) 2005-12-28 2010-11-02 3M Innovative Properties Company Encapsulated chromonic particles
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co CONJUGATES TO MODIFY IMMUNE REACTIONS
US8329721B2 (en) * 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
CA2646156C (en) 2006-03-22 2016-05-24 Medigene Ag Treatment of triple receptor negative breast cancer
US20070243258A1 (en) * 2006-04-13 2007-10-18 3M Innovative Properties Company Method and apparatus for forming crosslinked chromonic nanoparticles
US20070275185A1 (en) * 2006-05-23 2007-11-29 3M Innovative Properties Company Method of making ordered nanostructured layers
US8178539B2 (en) * 2006-09-06 2012-05-15 3M Innovative Properties Company Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
CN101568351B (zh) * 2006-12-22 2012-05-30 3M创新有限公司 控制释放的组合物和方法
WO2009139939A2 (en) * 2008-02-22 2009-11-19 The University Of North Carolina At Chapel Hill Hybrid nanoparticles as anti-cancer therapeutic agents and dual therapeutic/imaging contrast agents
PL2395843T3 (pl) 2009-02-13 2018-01-31 Monsanto Technology Llc Kapsułkowanie herbicydów do zmniejszenia uszkodzeń upraw
WO2010129728A2 (en) * 2009-05-06 2010-11-11 3M Innovative Properties Company Articles with shell structures including a cell extractant and biodetection methods thereof
DK2606047T3 (en) 2010-08-17 2017-03-27 3M Innovative Properties Co COMPOSITIONS AND FORMULATIONS WITH LIPIDIZED IMMUNE RESPONSE-MODIFIING COMPOUND AND PROCEDURES THEREOF
PL2605646T3 (pl) 2010-08-18 2017-01-31 Monsanto Technology Llc Wczesne zastosowanie kapsułkowych pochodnych acetamidu w celu zmniejszenia uszkodzeń upraw
EP3153180A1 (en) 2011-06-03 2017-04-12 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
BR112013031028A2 (pt) 2011-06-03 2016-11-29 3M Innovative Properties Co conectores heterobifuncionais com segmentos de polietileno glicol e conjugados de modificadores de resposta imunológica feitos a partir deles
EP3494974B1 (en) 2011-07-08 2023-10-18 The University of North Carolina at Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
CN105873569B (zh) 2013-11-06 2020-07-28 芝加哥大学 用于化疗剂、核酸和光敏剂的递送或共递送的纳米级载体
MX383040B (es) 2014-01-27 2025-03-13 Monsanto Technology Llc Concentrados herbicidas acuosos.
US10206871B2 (en) 2014-10-14 2019-02-19 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof
US10806694B2 (en) 2014-10-14 2020-10-20 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
EP3291838A4 (en) * 2015-05-05 2019-01-02 B.G. Negev Technologies and Applications Ltd. Anionic nanoparticles for use in the delivery of anionic small molecule drugs
CN109310702A (zh) 2016-05-20 2019-02-05 芝加哥大学 用于化学疗法、靶向疗法、光动力疗法、免疫疗法和它们的任何组合的纳米颗粒
MX2019015014A (es) 2017-06-13 2020-02-26 Monsanto Technology Llc Herbicidas microencapsulados.
WO2019028250A1 (en) 2017-08-02 2019-02-07 The University Of Chicago NOMOGENEOUS ORGANOMETALLIC ORGANOMETRIC ORGANOMETRIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RODIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF
CA3086439A1 (en) 2017-12-20 2019-06-27 3M Innovative Properties Company Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
UA129154C2 (uk) 2019-01-30 2025-01-29 Монсанто Текнолоджі Ллс Мікрокапсульовані ацетамідні гербіциди

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2512572A (en) * 1950-06-20 Substituted pteridines and method
US4030812A (en) * 1975-06-16 1977-06-21 Minnesota Mining And Manufacturing Company Lyotropic birefringent films
US4031092A (en) * 1975-06-16 1977-06-21 Minnesota Mining And Manufacturing Company 1,3-Bis-(carboxy-phenylamino)-s-triazines
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5756747A (en) * 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5037986A (en) * 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US4988815A (en) * 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
DK0553202T3 (da) * 1990-10-05 1995-07-03 Minnesota Mining & Mfg Fremgangsmåde til fremstilling af imidazo(4,5-c)quinolin-4-aminer
US5175296A (en) * 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
DE4211475A1 (de) * 1991-12-14 1993-06-17 Asta Medica Ag Pulverinhalator
US5352461A (en) * 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
DK0708772T3 (da) * 1993-07-15 2000-09-18 Minnesota Mining & Mfg Imidazo[4,5,-c]pyridin-4-aminer
EP0708805B9 (en) * 1993-07-15 2012-03-21 Minnesota Mining And Manufacturing Company Seals for use in an aerosol delivery device
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5482936A (en) * 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
US5741908A (en) * 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
US5693811A (en) * 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
JP4667543B2 (ja) * 1996-07-03 2011-04-13 大日本住友製薬株式会社 新規プリン誘導体
US6387938B1 (en) * 1996-07-05 2002-05-14 Mochida Pharmaceutical Co., Ltd. Benzimidazole derivatives
JP4391592B2 (ja) * 1996-10-25 2009-12-24 スリーエム カンパニー Ｔｈ２介在性および関連疾患治療のための免疫応答修飾化合物
US5939090A (en) * 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
US6069149A (en) * 1997-01-09 2000-05-30 Terumo Kabushiki Kaisha Amide derivatives and intermediates for the synthesis thereof
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6248364B1 (en) * 1997-04-07 2001-06-19 3M Innovative Properties Company Encapsulation process and encapsulated products
US6426334B1 (en) * 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
EP1003531B1 (en) * 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
US5948487A (en) * 1997-09-05 1999-09-07 3M Innovative Properties Company Anisotropic retardation layers for display devices
JP4375901B2 (ja) * 1997-11-28 2009-12-02 大日本住友製薬株式会社 新規な複素環化合物
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
TW572758B (en) * 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2000119271A (ja) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
US6214499B1 (en) * 1998-09-11 2001-04-10 Eastman Kodak Company Liquid crystalline filter dyes for imaging elements
US6180295B1 (en) * 1998-09-11 2001-01-30 Eastman Kodak Company Liquid crystalline filter dyes for imaging elements
US6245399B1 (en) * 1998-10-14 2001-06-12 3M Innovative Properties Company Guest-host polarizers
PL349773A1 (en) * 1999-01-08 2002-09-09 3M Innovative Properties Co Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6451810B1 (en) * 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6338443B1 (en) * 1999-06-18 2002-01-15 Mercury Enterprises, Inc. High efficiency medical nebulizer
DE60017259T2 (de) * 1999-08-13 2005-12-08 Hybridon, Inc., Cambridge Modulation der CPG-Oligonukleotid-vermittelten Immunstimulation durch Positionsbedingte Modifikation von Nukleosiden
US6574044B1 (en) * 1999-10-25 2003-06-03 3M Innovative Properties Company Polarizer constructions and display devices exhibiting unique color effects
US6538714B1 (en) * 1999-10-25 2003-03-25 3M Innovative Properties Company Dual color guest-host polarizers and devices containing guest-host polarizers
US6376669B1 (en) * 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
AU1763701A (en) * 1999-11-12 2001-06-06 3M Innovative Properties Company Liquid crystal alignment structures and optical devices containing same
DE10036282A1 (de) * 2000-07-26 2002-02-07 Bosch Gmbh Robert Verfahren und Vorrichtung zur Steuerung einer Antriebseinheit
US20020055517A1 (en) * 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
US6488866B1 (en) * 2000-11-08 2002-12-03 3M Innovative Properties Company Liquid crystal materials and alignment structures and optical devices containing same
US6545016B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6525064B1 (en) * 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6545017B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6411354B1 (en) * 2001-05-11 2002-06-25 Kent State University Bulk alignment of lyotropic chromonic liquid crystals
US6673398B2 (en) * 2001-05-14 2004-01-06 Kent State University Alignment of lyotropic chromonic liquid crystals at surfaces as monolayers and multilayered stacks
WO2003045968A1 (en) * 2001-11-27 2003-06-05 Anadys Pharmaceuticals, Inc. 3-β-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF

Also Published As

Publication number Publication date
JP2007500712A (ja) 2007-01-18
EP1651185A1 (en) 2006-05-03
EP1651035A2 (en) 2006-05-03
WO2005011629A1 (en) 2005-02-10
CA2533128A1 (en) 2005-02-10
BRPI0413164A (pt) 2006-10-03
WO2005012488A2 (en) 2005-02-10
AU2004261987A1 (en) 2005-02-10
AU2004261243A1 (en) 2005-02-10
RU2006102187A (ru) 2006-08-10
RU2006102188A (ru) 2006-07-10
MXPA06001054A (es) 2006-04-24
MXPA06001004A (es) 2006-04-27
WO2005012488A3 (en) 2005-05-26
KR20060056354A (ko) 2006-05-24
IL173301A0 (en) 2006-06-11
JP2007500713A (ja) 2007-01-18
US20080039533A1 (en) 2008-02-14
KR20060054371A (ko) 2006-05-22
US20080063714A1 (en) 2008-03-13
CA2534042A1 (en) 2005-02-10
BRPI0413143A (pt) 2006-10-03

Similar Documents

Publication Publication Date Title
AP2089A (en) Compositions and methods for combination antiviraltherapy
TWI347202B (en) Controlled release preparation
GB0218157D0 (en) Compositions for controlled release
EP1633718A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING TGF-S
PL377333A1 (pl) Preparaty depot o kontrolowanym uwalnianiu
GB0406819D0 (en) Controlled release compositions
GB0411940D0 (en) Methods and compositions
GB0416550D0 (en) Encapsulation process and encapsulated compositions
AU2003256805A8 (en) Compounds compositions and methods
GB0302738D0 (en) Composition
GB0324918D0 (en) Composition
PL376840A1 (pl) Kompozycja farmaceutyczna o przedłużonym uwalnianiu
GB0324897D0 (en) Composition
GB0322033D0 (en) Composition
MY145151A (en) Composition
EP1706111A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
AU2002365136A8 (en) Compositions and methods for controlled release
GB0309317D0 (en) Composition
GB0325942D0 (en) Compositions and uses thereof
GB0322044D0 (en) Controlled release compositions
GB0326815D0 (en) Composition
GB0306312D0 (en) Composition
GB0404470D0 (en) Composition
GB0215656D0 (en) Controlled release composition
GB0311354D0 (en) Controlled release formulations